{"id":54955,"date":"2023-03-17T18:04:14","date_gmt":"2023-03-17T17:04:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/"},"modified":"2023-03-17T18:04:14","modified_gmt":"2023-03-17T17:04:14","slug":"cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/","title":{"rendered":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms"},"content":{"rendered":"<div>\n<p>COQUITLAM, British Columbia&#8211;(BUSINESS WIRE)&#8211;Following three days of failed negotiations, CUPE 561 says its members who work for First Transit will commence a full walkout on Monday. HandyDART will operate at essential service levels for passengers requiring treatment for cancer, multiple sclerosis, and renal dialysis. All other transit services in the Fraser Valley will cease indefinitely until a fair deal is reached, the union said.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/5\/CUPE_LOGO_VERY_GOOD.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg\"><\/a><\/p>\n<p>\nCUPE 561 President Jane Gibbons described the full shutdown as a result of the company\u2019s intransigence at the table.\n<\/p>\n<p>\n\u201cThis employer has completely refused to meaningfully discuss the regional wage disparity and lack of a pension,\u201d said Gibbons. \u201cIt\u2019s gotten so bad that we\u2019re left with no alternative but to shut down services.\u201d\n<\/p>\n<p>\nFirst Transit, a U.S.-based, for-profit company subcontracted by BC Transit, was recently purchased by Transdev, a global corporation owned by a French sovereign wealth fund that has $1.3 trillion in assets\u2014an amount equal to last year\u2019s GDP for Australia and greater than the GDP of Spain or Indonesia.\n<\/p>\n<p>\n\u201cWe find it hard to believe that a company with this much wealth refuses to pay our members what other transit operators in this region make. Without fair wages, public transit in the Fraser Valley will continue to suffer,\u201d added Gibbons.\n<\/p>\n<p>\nOn March 16, BC Transit issued a statement to <i>Fraser Valley Today<\/i> expressing confidence in Transdev and its subsidiary\u2019s operations in the region.\n<\/p>\n<p>\n\u201cGiven First Transit\u2019s steadfast refusal to address the concerns of our members, it\u2019s clear that BC Transit\u2019s confidence in Transdev is grossly misplaced. In our mind, BC Transit\u2014a provincial Crown corporation responsible for public transit services\u2014is abandoning the communities it is entrusted to serve. It is leaving our community and transit users at the mercy of a profit-driven foreign conglomerate with no connection to the Fraser Valley.\u201d\n<\/p>\n<p>\ncope491\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nLiam O\u2019Neill, CUPE National Representative: 672.514.5426<br \/>\n<br \/>Dan Gawthrop, CUPE Communications Representative: 604.999.6132\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>COQUITLAM, British Columbia&#8211;(BUSINESS WIRE)&#8211;Following three days of failed negotiations, CUPE 561 says its members who work for First Transit will commence a full walkout on Monday. HandyDART will operate at essential service levels for passengers requiring treatment for cancer, multiple sclerosis, and renal dialysis. All other transit services in the Fraser Valley will cease indefinitely &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54955","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"COQUITLAM, British Columbia&#8211;(BUSINESS WIRE)&#8211;Following three days of failed negotiations, CUPE 561 says its members who work for First Transit will commence a full walkout on Monday. HandyDART will operate at essential service levels for passengers requiring treatment for cancer, multiple sclerosis, and renal dialysis. All other transit services in the Fraser Valley will cease indefinitely ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-17T17:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms\",\"datePublished\":\"2023-03-17T17:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/\"},\"wordCount\":332,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005274\\\/en\\\/837743\\\/21\\\/CUPE_LOGO_VERY_GOOD.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/\",\"name\":\"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005274\\\/en\\\/837743\\\/21\\\/CUPE_LOGO_VERY_GOOD.jpg\",\"datePublished\":\"2023-03-17T17:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005274\\\/en\\\/837743\\\/21\\\/CUPE_LOGO_VERY_GOOD.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230317005274\\\/en\\\/837743\\\/21\\\/CUPE_LOGO_VERY_GOOD.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/","og_locale":"en_US","og_type":"article","og_title":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend","og_description":"COQUITLAM, British Columbia&#8211;(BUSINESS WIRE)&#8211;Following three days of failed negotiations, CUPE 561 says its members who work for First Transit will commence a full walkout on Monday. HandyDART will operate at essential service levels for passengers requiring treatment for cancer, multiple sclerosis, and renal dialysis. All other transit services in the Fraser Valley will cease indefinitely ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-17T17:04:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms","datePublished":"2023-03-17T17:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/"},"wordCount":332,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/","url":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/","name":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg","datePublished":"2023-03-17T17:04:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230317005274\/en\/837743\/21\/CUPE_LOGO_VERY_GOOD.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cupe-561-takes-aim-at-first-transit-parent-company-as-indefinite-shutdown-looms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"CUPE 561 takes aim at First Transit parent company as indefinite shutdown looms"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54955"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54955\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}